AURA News and Press, Aura Biosciences Inc. From 02/09/22

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura, will participate in a f...

Clearside Biomedical reported positive safety data from phase 1/2a study using SCS microinjector for suprachoroidal delivery in patients with wet age-related macular degeneration. Clearside Biomedical and its partner Bausch & Lomb received FDA approval of first suprachoroidal inje...

Aura Biosciences (NASDAQ:AURA): Q3 GAAP EPS of -$28.33 misses by $27.88. As of September 30, 2021, Aura had cash and cash equivalents totaling $81.8 million. Aura raised $86.9 million in gross proceeds from the IPO. Aura believes its current cash and cash equivalents are sufficient to fund th...

Presented Final Data from Phase 1b/2 Trial of AU-011 in Choroidal Melanoma at the American Academy of Ophthalmology’s Annual Meeting Completed Initial Public Offering to Fund Pivotal Program for AU-011 in Choroidal Melanoma and Earlier Stage Oncology Pipeline ...

BTIG has initiated Aura Biosciences (NASDAQ:AURA) with a buy rating citing the company's novel targeted oncology platform. The firm has a $38 price target (~112% upside). Analyst Bert Hazlett speaks highly of Aura's lead candidate AU-011 (belzupacap sarotalocan), a virus-like drug conjugate i...

Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications including ocular and urologic cancers, today announced that Elisabet de los Pinos, Chief Executive Officer...

Aura Biosciences (AURA -7.9%) is trading lower despite buy-equivalent ratings issued by several Wall Street analysts as the company faces the expiry of its post-IPO quiet period. BTIG analyst Bert Hazlett has initiated the coverage on Aura (NASDAQ:AURA) with a Buy recommendation, highlighting...

Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...

Presentations Include Final Safety and Efficacy Data from the Phase 1b/2 Trial using Intravitreal Administration and Updated Safety Data from the Phase 2 Trial using Suprachoroidal Administration Aura Biosciences, a clinical-stage oncology company developing a novel class of...